stoxline Quote Chart Rank Option Currency Glossary
  
Aura Biosciences, Inc. (AURA)
6.43  -0.02 (-0.31%)    12-05 16:00
Open: 6.48
High: 6.505
Volume: 90,688
  
Pre. Close: 6.45
Low: 6.375
Market Cap: 408(M)
Technical analysis
2025-12-05 4:46:15 PM
Short term     
Mid term     
Targets 6-month :  7.73 1-year :  9.03
Resists First :  6.62 Second :  7.73
Pivot price 5.9
Supports First :  5.72 Second :  5.17
MAs MA(5) :  6.28 MA(20) :  5.81
MA(100) :  6.24 MA(250) :  0
MACD MACD :  0.1 Signal :  0
%K %D K(14,3) :  82.6 D(3) :  73.6
RSI RSI(14): 60.5
52-week High :  8.6 Low :  4.34
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ AURA ] has closed below upper band by 21.2%. Bollinger Bands are 112.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 6.51 - 6.55 6.55 - 6.58
Low: 6.29 - 6.33 6.33 - 6.37
Close: 6.37 - 6.44 6.44 - 6.5
Company Description

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Headline News

Mon, 24 Nov 2025
Aura Biosciences (NASDAQ: AURA) CEO Fireside Chat at Evercore Healthcare Conf. 2025 - Stock Titan

Mon, 24 Nov 2025
Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewswire

Mon, 17 Nov 2025
Top Executive Makes Bold Move with Aura Biosciences Stock Sale! - TipRanks

Sat, 15 Nov 2025
Aura Biosciences: Bringing Not-Quite-Viruses Closer To Fruition In Cancer (NASDAQ:AURA) - Seeking Alpha

Fri, 14 Nov 2025
Buy Rating on Aura Biosciences Inc. Driven by Promising Pipeline and Strategic Expansion in Ocular Oncology - TipRanks

Thu, 13 Nov 2025
Aura Biosciences Reports Q3 2025 Financial Results - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 64 (M)
Shares Float 37 (M)
Held by Insiders 1.8 (%)
Held by Institutions 84.5 (%)
Shares Short 2,920 (K)
Shares Short P.Month 3,140 (K)
Stock Financials
EPS -1.91
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.49
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -35.9 %
Return on Equity (ttm) -64.3 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.77
Qtrly Earnings Growth 0 %
Operating Cash Flow -88 (M)
Levered Free Cash Flow -51 (M)
Stock Valuations
PE Ratio -3.37
PEG Ratio 0
Price to Book value 2.58
Price to Sales 0
Price to Cash Flow -4.63
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android